LABT CFO discloses initial share and option holdings
Lakewood-Amedex Biotherapeutics Inc. Chief Financial Officer Peter Ceccacci filed an initial ownership report showing his equity position in the company.
Rhea-AI Filing Summary
Lakewood-Amedex Biotherapeutics Inc. Chief Financial Officer Peter Ceccacci filed an initial ownership report showing his equity position in the company. He directly holds 468,148 shares of common stock.
He also holds several direct stock options on common shares, including 202,703 underlying shares at an exercise price of $2.31 per share expiring in 2035, and additional options at exercise prices of $2.13 and $2.78 per share with expirations between 2031 and 2034. The filing records holdings only and does not show new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Ceccacci Peter
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Common Stock; $0.0001 par value | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 384,292 contracts (Direct);
Common Stock; $0.0001 par value — 468,148 shares (Direct)
Key Figures
Direct common shares held: 468,148 shares
Largest option grant: 202,703 underlying shares at $2.31
Option grant at $2.13 (2034): 29,561 underlying shares at $2.13
+3 more
6 metrics
Direct common shares held
468,148 shares
Total common stock directly owned by CFO Peter Ceccacci
Largest option grant
202,703 underlying shares at $2.31
Exercise price $2.31 per share, expires July 1, 2035
Option grant at $2.13 (2034)
29,561 underlying shares at $2.13
Exercise price $2.13 per share, expires March 13, 2034
Option grant at $2.13 (2033)
50,676 underlying shares at $2.13
Exercise price $2.13 per share, expires March 1, 2033
Additional option at $2.13 (2033)
67,568 underlying shares at $2.13
Exercise price $2.13 per share, expires March 1, 2033
Option grant at $2.78
33,784 underlying shares at $2.78
Exercise price $2.78 per share, expires March 1, 2031
Key Terms
Option (right to buy), underlying security shares, exercise price, direct ownership, +1 more
5 terms
Option (right to buy) financial
""security_title": "Option (right to buy)""
exercise price financial
""conversion_or_exercise_price": "2.3100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
direct ownership financial
""ownership_type": "direct""
Form 3 regulatory
"INSIDER FILING DATA (Form 3):"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the LABT Form 3 filing by CFO Peter Ceccacci show?
The Form 3 shows that Lakewood-Amedex Biotherapeutics CFO Peter Ceccacci directly holds 468,148 common shares plus several option grants on additional shares. It is an initial ownership report, recording his existing equity position rather than new buying or selling activity.
What stock options are reported for the LABT CFO in this Form 3?
The filing lists several direct options, including one covering 202,703 underlying common shares at a $2.31 exercise price expiring in 2035, and additional options at $2.13 and $2.78 per share expiring between 2031 and 2034, all on Lakewood-Amedex common stock.
Does the LABT CFO Form 3 indicate any recent stock purchases or sales?
No, the Form 3 reflects holdings only with transaction codes classified as unknown and no buy or sell entries. It reports the CFO’s existing common stock and option positions rather than documenting new market transactions or changes from prior ownership levels.
Are the LABT CFO’s options in the Form 3 direct or indirect holdings?
All reported option positions in the Form 3 are labeled as direct ownership with ownership code “D.” Each option relates to Lakewood-Amedex common stock as the underlying security, with specified exercise prices and expiration dates disclosed for the underlying share amounts.
What is the exercise price and expiration of the largest LABT option grant reported?
The largest option position reported covers 202,703 underlying common shares with an exercise price of $2.31 per share and an expiration date of July 1, 2035. This option is held directly by CFO Peter Ceccacci according to the Form 3 data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
